Related Experiment Video

Updated: May 20, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Dual blockade of HER2 - twice as good or twice as toxic?

M Fralick1, J F Hilton, N Bouganim

  • 1Faculty of Medicine, University of Toronto, Canada. mike.fralick@mail.utoronto.ca

Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 4, 2012
PubMed

Insights

HER2-positive breast cancer treatment faces resistance to targeted therapies like trastuzumab. Combining agents offers improved response rates but increases toxicity, necessitating further research into resistance mechanisms and combination strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Approximately 20% of breast cancers overexpress Human Epidermal growth factor Receptor 2 (HER2).
  • Trastuzumab and lapatinib have significantly improved outcomes for HER2-positive breast cancer patients.
  • De novo and acquired resistance to HER2-targeted therapies remain significant clinical challenges.

Purpose of the Study:

  • To review the mechanisms underlying resistance to HER2-targeted therapies.
  • To explore the preclinical rationale for combining HER2-targeted agents.
  • To summarize clinical trial data on combination therapies for HER2-positive breast cancer.

Main Methods:

  • Literature review of mechanisms of HER2 resistance.
  • Analysis of preclinical studies investigating combination therapies.
  • Summary of clinical trial outcomes for trastuzumab combinations.

Main Results:

  • Resistance mechanisms involve complex interplay within the HER family.
  • Combination therapies show potential for improved response rates and survival.
  • Increased toxicity is a notable concern with combination approaches.

Conclusions:

  • Understanding HER2 resistance is crucial for advancing treatment.
  • Multi-targeted inhibition strategies are promising but require careful toxicity management.
  • Further clinical investigation is needed to optimize combination therapies for HER2-positive breast cancer.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...